The importance of using the oral glucose tolerance test when assessing the glycemic profile in patients with adrenal incidentaloma

在评估肾上腺偶发瘤患者的血糖谱时,口服葡萄糖耐量试验的重要性

阅读:1

Abstract

INTRODUCTION: There are limited data regarding the role of oral glucose tolerance test (OGTT) in classifying glycemic alterations in patients with adrenal incidentaloma (AI). This study aims to compare the frequency of dysglycemia [pre-diabetes mellitus (DM) and DM] among patients with non-functioning adrenal incidentalomas (NFAI), mild autonomous cortisol secretion (MACS), and controls; and to assess the area under the curve (AUC) in the OGTT and determine whether the OGTT was decisive in diagnosing dysglycemia in each population. METHODS: A cross-sectional study was conducted on 65 NFAI (1mg-dexamethasone suppression test [DST] ≤1.8μg/dL), 45 MACS (1mg-DST ≥1.9μg/dL), and 56 controls. The control group was selected based on normal adrenal imaging. Patients were classified as normoglycemic or dysglycemic based on fasting glucose, glycated hemoglobin, and OGTT. RESULTS: AUC >290mg.h/dL was found in 75% of MACS, 55% of NFAI, and 22% of controls (p=0.008). The presence of AI was determinant for this result. Glucose levels ≥155 mg/dL at the 1-hour during the OGTT were observed in 75% of MACS, 65% of NFAI, and 28% of controls (p=0.01). Dysglycemia frequency was higher in MACS and NFAI than controls (91.1 vs. 90.8 vs. 73.2%; p=0.01). The OGTT changed the classification in 27% of MACS, 23% of NFAI, and 3% of controls (p=0.03). Presence of AI increased the odds ratio for benefiting from OGTT to obtain a more accurate dysglycemia classification by 9.5 times. CONCLUSION: Patients with AI had a higher dysglycemia frequency, and a significant number of these patients benefited from OGTT in classifying glycemic alterations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。